New and modified interferon alfas: Preclinical and clinical data

Current Oncology Reports

Volumn 5, Issue 2, 2003, Pages 108-113

  Masci, Paul ^b   Bukowski, Ronald M ^b   Patten, Phillip A ^b   Osborn, Blaire L ^b   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA 2 MICROGLOBULIN; MESSENGER RNA; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; FATIGUE; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; METASTASIS; MYALGIA; NAUSEA; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VOMITING; DRUG SCREENING;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; SERUM ALBUMIN;

EID: 0642377751     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0097-4     Document Type: Review

References (17)

1. Sarkar M, Masci P, Borden EC: Interferons in cancer drug therapies: key contributions of recombinant biotechnology. New York: J. Wiley and Sons; chapter in press.
2. Mitchell MS: Biologic agents approved for use. In Cancer Treatment, edn 5. Edited by Haskell CM. Philadelphia: WB Saunders; 2001:215-219.
3. Borden EC, Williams BRG: Interferons. In Cancer Medicine, edn 5. Edited by Holland JF. Hamilton, ON: BC Decker; 2000:815-824.
4. Pestka S: The human interferon-alfa species and hybrid proteins. Semin Oncol 1997, 24(Suppl 9):S9-4-S9-17.
5. Hawkins MJ, Borden EC, Merritt JA, et al.: Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. J Clin Oncol 1984, 2:221-226.
6. Bukowski RM, Tendler C, Cutler D, et al.: Treating cancer with PEG Intron. Cancer 2002, 95:389-396.
7. Wang Y, Youngster S, Bausch J, et al.: Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 200, 39:10634-10640.
8. Bailon F, Palleroni A, Schaffer CA, et al.: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001, 12:195-202.
9. Glue P, Fang JWS, Rouzier-Panis R, et al.: Pegylated interferon-alfa2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 200, 68:556-567.
10. Bukowski R, Ernstoff MS, Gore ME, et al.: Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002, 20:3841-3849.
11. Lindsay KL, Trepo C, Heintges T, et al.: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395-403.
12. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
13. Talpaz M, O'Brien S, Rose E, et al.: Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 2001, 98:1708-1713.
14. Kurtzman AL, Govindarajan S, Vahle K, et al.: Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotechnol 2001, 12:361-370.
15. Chang CC, Chen TT, Cox BW, et al.: Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999, 17:793-797.
16. Heinrichs V, Chen T, Patten PA: W 01/25438 A2 [patent].
17. Osborn BL, Olsen HS, Nardelli B, et al.: Pharmacokinetic and pharmacodynamic studies of a human serum albunin-interferon alfa fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002, 303:540-548.